Abcam, ab283511, Anti-NMT2 antibody [EPR24372-10] - BSA and Azide free

Size: 100µg / 1mg
Rabbit Recombinant Monoclonal NMT2 antibody. Carrier free. Suitable for WB and reacts with Mouse, Rat, Human samples.
Key facts
Host species:Rabbit,
Clonality:Monoclonal,
Clone number:EPR24372-10,
Isotype:IgG,
Carrier free:Yes,
Reacts with:Rat, Mouse, Human,
Applications:WBSee reactivity dataSee the reactivity data table below for information on validated species and application combinations.,
Immunogen:The exact immunogen used to generate this antibody is proprietary information.

Product details:
ab283511 is the carrier-free version of
ab270957
Patented technology
Our RabMAb
technology is a patented hybridoma-based technology for making rabbit monoclonal antibodies. For details on our patents, please refer to
RabMAb® patents
What are the advantages of a recombinant monoclonal antibody?
This product is a recombinant monoclonal antibody, which offers several advantages including:
- High batch-to-batch consistency and reproducibility
- Improved sensitivity and specificity
- Long-term security of supply
- Animal-free batch production
For more information, read more on
recombinant antibodies
Conjugation ready
Our carrier-free antibodies are typically supplied in a PBS-only formulation, purified and free of BSA, sodium azide and glycerol. This conjugation-ready format is designed for use with fluorochromes, metal isotopes, oligonucleotides, and enzymes, which makes them ideal for antibody labelling, functional and cell-based assays, flow-based assays (e.g. mass cytometry) and Multiplex Imaging applications.
Use our
conjugation kits
for antibody conjugates that are ready-to-use in as little as 20 minutes with 1 minute hands-on-time and 100% antibody recovery: available for fluorescent dyes, HRP, biotin and gold.
Compatibility
This product is compatible with the Maxpar
Antibody Labeling Kit from Fluidigm, without the need for antibody preparation. Maxpar
is a trademark of Fluidigm Canada Inc.

Properties and Storage Information:
Form-Liquid, Purification technique-Affinity purification Protein A, Storage buffer-pH: 7.2 - 7.4Constituents: PBS, Shipped at conditions-Blue Ice, Appropriate short-term storage conditions-+4°C, Appropriate long-term storage conditions-+4°C

Supplementary Information:
This supplementary information is collated from multiple sources and compiled automatically.
N-myristoyltransferase 2 or NMT2 is an enzyme that catalyzes N-terminal myristoylation. It transfers myristic acid a 14-carbon saturated fatty acid to the N-terminal glycine residue of substrate proteins. This modification influences the protein's function stability and subcellular localization. NMT2 has a structure with an approximate mass of 53 kDa. It is expressed in various tissues including the liver and the brain contributing to diverse biological processes.
Biological function summary
NMT2 participates in the post-translational modification of proteins which impacts cellular signaling and protein-protein interactions. It exists within a myristoylation enzyme complex working alongside its isoform NMT1 which complements its activity. NMT2 influences pathways involving protein trafficking and cell growth playing a role in membrane localization and signal transduction of several key proteins.
Pathways
NMT2 actively engages in the Wnt signaling and protein kinase C (PKC) pathways. These pathways contribute to regulating cell fate decisions and cellular responses to extracellular signals. NMT2 shares pathway interaction with proteins like beta-catenin in the Wnt pathway and is linked with PKC isoforms within the PKC pathway. This involvement affects cytoskeleton organization cellular proliferation and apoptosis.
Scientists have observed that alterations in NMT2 activity associate with various diseases including cancer and neurological disorders. In cancer abnormal NMT2 expression impacts cancer cell survival and metastasis. In neurological disorders changes in myristoylation affect synaptic function and neuronal signaling. NMT2 interacts with proteins like beta-catenin in cancer progression and synaptophysin in neurological conditions. These connections highlight NMT2 as a potential therapeutic target for drug development.